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Abstract
Background: A diverse class of engineered nanomaterials (ENMs) exhibiting a wide array of physical-chemical
properties that are associated with toxicological effects in experimental animals is in commercial use. However, an
integrated framework for human health risk assessment (HHRA) of ENMs has yet to be established. Rodent 2-year
cancer bioassays, clinical chemistry, and histopathological endpoints are still considered the ‘gold standard’ for
detecting substance-induced toxicity in animal models. However, the use of data derived from alternative
toxicological tools, such as genome-wide expression profiling and in vitro high-throughput assays, are gaining
acceptance by the regulatory community for hazard identification and for understanding the underlying
mode-of-action. Here, we conducted a case study to evaluate the application of global gene expression data
in deriving pathway-based points of departure (PODs) for multi-walled carbon nanotube (MWCNT)-induced
lung fibrosis, a non-cancer endpoint of regulatory importance.
Methods: Gene expression profiles from the lungs of mice exposed to three individual MWCNTs with
different physical-chemical properties were used within the framework of an adverse outcome pathway (AOP)
for lung fibrosis to identify key biological events linking MWCNT exposure to lung fibrosis. Significantly
perturbed pathways were categorized along the key events described in the AOP. Benchmark doses (BMDs)
were calculated for each perturbed pathway and were used to derive transcriptional BMDs for each MWCNT.
Results: Similar biological pathways were perturbed by the different MWCNT types across the doses and
post-exposure time points studied. The pathway BMD values showed a time-dependent trend, with lower
BMDs for pathways perturbed at the earlier post-exposure time points (24 h, 3d). The transcriptional BMDs
were compared to the apical BMDs derived by the National Institute for Occupational Safety and Health
(NIOSH) using alveolar septal thickness and fibrotic lesions endpoints. We found that regardless of the type
of MWCNT, the BMD values for pathways associated with fibrosis were 14.0–30.4 μg/mouse, which are
comparable to the BMDs derived by NIOSH for MWCNT-induced lung fibrotic lesions (21.0–27.1 μg/mouse).
Conclusions: The results demonstrate that transcriptomic data can be used to as an effective mechanism-based
method to derive acceptable levels of exposure to nanomaterials in product development when epidemiological
data are unavailable.
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Background
The increased production and use of engineered nano-
materials (ENMs) in industrial and consumer products
has raised concerns about potential health and envi-
ronmental risks posed by exposure to these materials.
ENMs exhibit size-associated properties. While the
chemical properties such as, solubility and chemical
structure are traditionally known to influence the tox-
icity of bulk chemical substances, the toxicity of ENMs
is influenced by their distinct physico-chemical proper-
ties, such as being insoluble (as opposed to soluble bulk
chemicals), and having a small size, large surface area,
and increased surface reactivity. Within the biological
microenvironment, these unique properties allow
ENMs to interact with surrounding biomolecules and
structures in a complex and non-specific manner. As a
result, ENMs are expected to be toxicologically dis-
tinct from soluble chemicals and more active than lar-
ger particles of similar chemical composition. Despite
this knowledge, a validated framework for human health
risk assessment (HHRA) of ENMs has yet to be estab-
lished. Sustained development of nanotechnology-enabled
products will be hampered by the lack of a pragmatic
risk assessment paradigm that can effectively address
the unique aspects of nanomaterial risk assessment in
a timely manner.
Given the unique properties of ENMs, standardized
toxicity testing methods developed originally for bulk
chemicals were tested for their suitability for investigating
ENM-induced effects [1–6]. Although, the Organization
for Economic Co-operation and Development (OECD)
has stated that in general the OECD guidelines developed
for bulk chemicals may be applicable to ENMs, based on
the types of endpoints studied, modifications and adjust-
ments are needed in regards to the sample preparation
and analysis. Consequently, significant efforts have
been made to develop novel methods, or to modify
existing in vivo and in vitro test methods, to assess
ENM toxicity [7]. However, validation of these new
methods has been challenging due to the lack of suf-
ficient amount of reference materials and harmonized
protocols. An additional challenge is the large number
of ENMs requiring immediate human health hazard
and risk assessment. Indeed, the generation of toxico-
logical data for each ENM variant using conventional
single end-point based methods is not practical. To
circumvent this problem, a strategy has been pro-
posed for ENMs that involves the use of high-content
omics tools or in vitro high-throughput assays to
examine the toxicity induced by well characterized
ENMs in short-term toxicity models for screening
and prioritization [8], a strategy that is in line with
the United States National Research Council’s vision
of a paradigm shift in toxicology [9].
Whole genome gene expression profiling allows for
the simultaneous analysis of changes in the expression
of all the genes in a tissue or cell type following
substance exposure. Numerous studies have employed
genomics methods, in combination with bioinformatics
tools for ontological and pathway analyses, to investigate
the underlying molecular mechanisms of action of
toxicants [10–14]. These studies have demonstrated that
global changes in gene expression following exposure to
a substance are associated with the development of
Labib toxicological phenotypes in a dose-dependent
manner [15].
In our previous studies, we used whole genome gene
expression profiling and bioinformatics analyses of mouse
models to study the specific particle properties that influ-
ence toxicity and to elucidate the mechanisms of pulmon-
ary response induced by various types of ENMs including:
nano-titanium dioxide particles (nanoTiO2) [16–18],
multiwalled carbon nanotubes (MWCNTs) [19, 20], and
carbon black (CB) [21–23]. These studies demonstrated
that the molecular perturbations at the gene expression
and pathway level leading to lung inflammation following
exposure to ENMs are the same regardless of the class of
ENM studied; however, the magnitude (number of genes
and the fold-change response) of the perturbation varies.
Subsequently, we conducted a meta-analysis of gene
expression data catalogued from 15 individual genomics
datasets describing lung responses to disease-inducing
chemical substances, pathogens, or ENMs in mouse
models, and identified gene expression signatures predict-
ive of disease-causing ENMs [24]. In another study, we
used a combination of bi-clustering of gene expression
data and gene set enrichment analyses methods to identify
gene sets in ENM-induced gene expression changes that
are similar to disease conditions [25]. The latter studies
demonstrated that gene expression data can be used to
predicting disease potential of ENMs before the pheno-
type is established, and therefore can be used to prioritize
ENMs for further toxicological investigation. Thus, the of
genomics tools to characterizing ENM-induced toxic
responses is well established.
The use of genomics approaches to provide informa-
tion on a chemical’s hazard and mode-of-action (MOA)
is gaining acceptance in the regulatory community;
however its utility in a regulatory context and a specific
paradigm for genomics-driven quantitative HHRA has
yet to be established. Approaches for quantitative
dose–response analysis of genomics endpoints have
been developed and methods to derive transcriptional
benchmark dose (BMD) values that could be applied
to quantitative risk assessment have been explored
[26–29]. Although several case studies [26, 28, 30]
have been conducted to demonstrate the potential use
of gene expression data in deriving points of departure
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(PODs) for risk assessment, and guidance documents to
describe the strategies and methods involved have been
developed, much more work is needed before full integra-
tion of genomics in routine quantitative HHRA of toxic
substances can be realized. In the interim, the value of
genomics data as supplementary information contributing
to the weight of evidence is recognized [31].
In the present case study, we explored the use of toxi-
cogenomics to establish PODs for MWCNT-induced
lung fibrosis, and assessed its relevance for HHRA of
MWCNTs. MWCNTs are widely used ENMs in indus-
trial and biomedical sectors. Short-term and sub-chronic
studies in rodents have shown that MWCNTs are bio-
persistent and induce various effects in lungs, including
persistent pulmonary inflammation, granulomas, and
lung fibrosis, following exposure via inhalation, instilla-
tion, or pharyngeal aspiration [32–35]. Occupational
exposure studies have estimated human CNT exposure
levels of 10 – 300 μg/m3 in facilities such as research
laboratories and production plants where CNTs are pro-
duced, processed, used, disposed of, or recycled [36–42]
(reviewed in [43]). The United States National Institute
for Occupational Safety and Health (NIOSH) recently
completed a HHRA for CNT-induced lung fibrosis that
takes into consideration existing toxicological data from
animal models [43]. We used this published report to
derive POD values for apical endpoints. For the deriv-
ation of genomics driven POD values, first, we used the
framework of adverse outcome pathway (AOP) to logic-
ally and systematically organise the mechanistic informa-
tion available in the literature concerning CNT-induced
lung fibrosis and the results of global transcriptomic
analyses conducted on mouse lungs exposed to three
individual types of MWCNTs [19, 34, 44]. The key bio-
logical events associated with one potential mechanism
linking the MWCNT exposure to the adverse outcome
of lung fibrosis were identified. Next, transcriptional
BMDs for perturbed biological pathways corresponding
to the key events in the hypothetical AOP for fibrosis
were calculated using data from dose–response and
time-series experiments on rodents exposed to the same
three types of MWCNTs [19, 44]. Finally, we compared
the PODs derived by NIOSH using traditional risk
assessment approaches to transcriptional PODs derived
via multiple genomics based approaches (Fig. 1). Our re-
sults provide foundational data and guidance to support
the use of transcriptional PODs in HHRA of ENMs.
Methods
Study design
The present study employed gene expression data from
three studies already published in the literature. No
Genomics Approaches
AOP-dependent approaches
select POD based on AOP 
relevant pathway
AOP-independent approaches
select PODs based on most 
sensitive or median pathway
MWCNT exposures
- adult male mice
NM-401
NRCWE-026
Mitsui-7
Route of exposure
Single intratracheal 
instillation
Dose groups and Time points
Time: 24hr, 3d, 28d Time: 24hr, 7d, 28d, 56d
Whole genome gene expression analysis
Dose-response analysis
Single pharyngeal aspiration
Statistical analysis
Pathway analysis
Incorporation into hypothetical AOP for lung fibrosis
Calculate BMD(L) for biological pathways
NIOSH Approach
NIOSH approach
select POD based on 
apical endpoint
MWCNT literature review
Calculate BMD(L) for 
pulmonary fibrosis 
endpoints
Characterization
Exposure
Toxicokinetics
Health effects
- Human
- Animal
Fig. 1 Comparison of traditional and genomics approaches for determining points of departure for exposure to MWCNT
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additional animal experiments or laboratory experiments
were conducted. Details on research conducted on
animals and ethics approvals obtained are described in
Poulsen et al. [19], Guo et al. [44], and Mercer et al.
[34]. In order to derive meaningful data for AOP assess-
ment and HHRA, both time-series and dose–response
data are required. We searched the literature for studies
that describe transcriptional lung responses to multiple
doses of MWCNTs at different post-exposure time-
points in a mouse model and found two relevant studies
[19, 44]. The analyses were restricted to mouse studies
to minimize the loss of information during the statistical
normalization of cross-species data and included only
those datasets that are publicly available and meet the
transcriptomic quality checks recommended by Bourdon-
Lacombe et al. [31]. Figure 1 shows the different ap-
proaches used in the present study to derive PODs.
Additional physico-chemical properties of the three
MWCNTs are listed in Additional file 1: Table S1. One
study that reported mouse lung fibrotic response to
MWCNT by histopathological and morphometric ana-
lyses was also included for the purposes of comparison of
transcriptomic approaches to apical endpoint-driven risk
assessment methods [34]. The study design of the three
individual studies considered in the analysis is briefly
described below.
Study 1. Poulsen et al. [19] investigated the
transcriptomic response of mouse lungs exposed to two
types of individual MWCNTs of different lengths:
NM-401 (4 ± 0.4 μm in length, European Union Joint
Research Centre, Ispra, Italy) and NRCWE-026
(0.8 ± 0.1 μm in length, Nanocyl NC7000 CNT,
Sambreville, Belgium). In this study, female C57BL/6
mice were exposed via single intratracheal instillation
to 18, 54, or 162 μg/mouse of NM-401 or NRCWE-026
dispersed in MilliQ water with 2 % serum. Control
mice were exposed to 2 % serum in MilliQ water only.
The selected doses reflect 1, 3, and 9 days of exposure
at the Danish eight-hour working day occupational
exposure limit of 3.5 mg/m3 for Printex90 carbon black
particles [45]. Mouse lung tissue was collected 24 h,
3 days, and 28 days post-exposure. Total RNA
extracted from the left lung lobe (N = 6 per treatment
group and time point) was hybridized to Agilent mouse
8 × 60 K oligonucleotide microarrays. LOWESS
normalization and MAANOVA analysis was conducted
to identify the significantly differentially expressed genes
(DEGs). The DEGs with false discovery rate (FDR)
adjusted P value of ≤ 0.05 and fold change of ≥ ± 1.5
were used in the downstream analysis by pathway and
ontology tools as described in Poulsen et al. [19].
Study 2. Guo et al. [44] investigated the transcriptomic
response of male C57BL/6 mouse lungs exposed via
pharyngeal aspiration to XNRI MWCNT-7, commonly
referred to as Mitsui-7 (3.86 μm in length, Mitsui &
Company). Briefly, mice were exposed to a single dose
of 10, 20, 40, or 80 μg/mouse of Mitsui-7 dispersed in
vehicle (Ca2+ and Mg2+ free phosphate buffered saline
supplemented with D-glucose, mouse serum albumin,
and 1,2 dipalmitoyl-sn-glycero-3-phosphocholine).
Control mice were exposed to dispersion vehicle only.
The 10 μg dose used in this study reflects occupational
exposure to MWCNTs for a time period between
9 months and 7.5 years based on the average daily
MWCNT workplace exposure data for a person
performing light work in an environment with
MWCNT aerosol of 4–40 μg/m3) [46]. Lung tissue was
collected 24 h, 7, 28, and 56 days post-exposure. Total
RNA extracted from the whole lung (N = 8 per treatment
group and time point) was hybridized to Agilent mouse
4 × 44 K oligonucleotide microarrays. This microarray
dataset has also been used in other studies by Snyder-
Talkington et al. [47, 48] and Dymacek et al. [49, 50].
The microarray dataset was downloaded from the GEO
database (www.ncbi.nlm.nih.gov/geo) (GSE29042) and
was reanalysed employing the same statistical methods as
Poulsen et al. [19] above to derive the list of DEGs. Genes
showing FDR P value ≤ 0.05 and fold change ≥ ± 1.5 were
used in the pathway and ontology analyses.
Study 3. Mercer et al. [34] investigated the pulmonary
fibrotic response in male C57BL/6 mice following
pharyngeal aspiration of 10, 20, 40, or 80 μg/mouse
Mitsui-7. The exposure regimen was the same as the
one by Guo et al. [44]. Lung tissues were fixed by
intratracheal perfusion of 10 % formalin. The left lobe
of the lung was embedded in paraffin, sectioned, and
stained with Sirius Red stain for the histopathological
and morphometric measurements. The average
thickness of Sirius Red positive connective tissue in
the alveolar regions was measured using quantitative
morphometric methods and the collagen fiber content
of granulomatous lesions in the airspaces was assessed
as total Sirius Red staining in the airspace.
Pathway analysis
Functional pathway analysis for classifying genes signifi-
cantly affected by the exposure to MWCNTs was
conducted using Ingenuity Pathway Analysis (IPA,
Ingenuity Systems, Redwood City, CA, USA). The canon-
ical pathways consisting of at least five DEGs and exhibit-
ing a Fisher’s Exact P value ≤ 0.05 were considered for
further calculation of pathway BMD values for the
AOP-dependent approaches.
Calculation of transcriptional BMDs
Since the purpose of this study was to assess the ap-
plicability of toxicogenomic data in quantitative risk
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assessment for MWCNT-induced lung fibrosis, BMD
modeling was conducted on each microarray dataset
using BMDExpress version 1.4.1 [51]. Briefly, the
BMD analysis was performed on present genes (defined as
those that had signal intensities at least three standard
deviations above the background non-murine control
spots on the array) that showed ANOVA P ≤ 0.05 for at
least one dose. Four dose–response models; Hill, Power,
Linear, and Polynomial (20 and 30) models were used
to assess the best fit. Selection of the best fit model
required: (a) a nested chi-squared test cut-off of 0.05,
(b) the lowest Akaike Information Criterion (AIC), (c)
goodness-of-fit P value > 0.1, and (d) the BMD was
lower than the highest dose. The benchmark response
factor was set to 1.349, which corresponds to a 10 %
change compared to controls [51]. The maximum number
of iterations, the convergence criteria for model fitting,
was set to a maximum of 250, and power was restricted
to ≥ 1. If the k parameter of the Hill model was less than
one third of the lowest dose used in an experiment [52],
the Hill model was flagged and subsequently excluded if
at least one other model had a p-value > 0.05. In the case
when no other model had a p value > 0.05, the Hill model
BMD was adjusted to ½ of the lowest BMD value. The
resulting BMDs for each gene were mapped to IPA canon-
ical pathways to assess biological relevance. Median BMD
and BMDL (lower confidence limit of BMD) values were
calculated for each IPA canonical pathway that had at
least five modeled DEGs.
Calculation of BMDs for apical endpoints
NIOSH conducted an extensive review of the literature
pertaining to the human health effects of occupational
exposures to both MWCNT and single walled CNTs
(SWCNT). BMD analysis was conducted on CNT-
induced alveolar septal thickness and other related
endpoints reflective of lung fibrosis using the US EPA’s
BMD software (BMDS, version 2.1.2) [53]. For dichot-
omous data, a benchmark response (BMR) of 10 %
excess risk was used and for continuous data, a BMR of
1.1 standard deviations above the control mean response
was used as an equivalent to a 10 % BMD estimated in
dichotomous data. Model fit was considered adequate if
goodness of fit P value was greater than 0.05.
Results and discussion
Proposed transcriptomics-driven regulatory testing
paradigm
Sustained development of products containing ENMs will
be impeded by the lack of a pragmatic risk assessment
paradigm that can effectively address the unique aspects
of nanomaterial risk assessment in a timely manner.
Fundamental understanding of the molecular mechanisms
underlying toxicity has become a central component of
proposed changes to human health risk assessment
(HHRA) challenges in the 21st century [9]. Global analyses
of perturbations in biological pathways, processes, and
functions are playing an increasingly important role in
dissecting toxicological mechanisms associated with
human health risks. In parallel, increasing emphasis
has been placed on dose–response modelling of global
transcriptional changes to identify the doses at which
critical tissue-level effects begin to occur [54, 55].
Here we propose an integrated approach that le-
verages advances in high-throughput transcriptomics,
dose–response modeling, and international initiatives to
develop AOPs of toxicological effects be used to address
the important risk assessment gaps for nanomaterials.
In a proof of concept study, we obtained publicly avail-
able genomics data from rodent pulmonary exposures to
MWCNT for BMD modelling of perturbed genes and
pathways. A BMD is the dose associated with a predeter-
mined response level. The statistical lower confidence
bound on the BMD (the 95 % lower bound on the
BMD) is the BMDL, which is equivalent to traditional
No Observed Adverse Effect Level (NOAEL) that is used
as a POD. Transcriptional BMDs were linked to key
events in a hypothetical AOP for pulmonary fibrosis
to assess their potential utility in selecting a POD for
nanomaterial HHRA.
As part of the first steps in deriving transcriptomics-
based BMDs for HHRA of MWCNT-induced lung fibro-
sis, we organised the vast amount of gene expression
data derived from the three studies [19, 44] in a system-
atic and logical manner using an AOP framework. This
enabled us to construct a hypothetical AOP describing
the various key events (as derived from gene expression
and pathway perturbation data) that may occur between
the initial exposure to MWCNTs and the development
of fibrotic lesions in the lungs (Fig. 2).
The lung constitutes a barrier between the host and
the environment. The alveolar capillary membrane
(ACM) plays a critical role in gas exchange and is
constantly exposed to inhaled or endogenous challenges.
Exposure-induced ACM injury and consequent loss of
structural integrity results in injury, inciting a repair
process that begins with extravasation of plasma into
lung tissue, activation of intrinsic and extrinsic coagu-
lation pathways, fibrin deposition, and establishment of
a provisional matrix. These steps involve the release of a
number of lipid mediators, cytokines, growth factors,
and chemo-attractants required for activation of various
immune cell types. If the primary insult leading to ACM
injury is removed, the deposited extracellular matrix
(ECM) is remodelled or reabsorbed. The epithelial and
endothelial cells re-establish their normal spatial orien-
tation on the basement membrane of the ACM, restor-
ing the integrity of the ACM, and complete the repair
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process [56]. However, persistent or recurrent injury
from repetitive or persistent exposure to an irritant leads
to a deregulated tissue repair process that can result in
lung fibrosis. As such, there exists no simplified mech-
anism that encompasses the pathogenesis of fibrosis in
all situations. For example, while fibrosis induced by the
inhalation of the high aspect ratio particle asbestos is
dependent on inflammatory mediators such as TNF-α
[57], cystic fibrosis is driven by a mutation in the CFTR
gene and may occur in the absence of inflammation
[58]. In idiopathic pulmonary fibrosis (IPF) the specific
cause and mechanism is unknown, although exposure to
chemicals and particulate matter is deemed a risk factor
for IPF [59]. Mechanistic studies that analyzed the
targeted inhibition of specific fibrotic mediators are
currently not extensive enough to form a complete
picture for in vivo models of particulate-induced fibrosis.
In general, what we know of pulmonary fibrosis is drawn
from the well-characterized murine model of bleomycin-
induced pulmonary fibrosis. Bleomycin exposure models
outline a process where there is an initial inflammatory
response characterized by macrophage- and epithelial
cell-derived cytokine production associated with in-
nate immunity. Disruption of these innate immune
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mechanisms, which include IL-1 and IL-6 signaling,
significantly attenuates fibrosis in the bleomycin model
[60–62]. This initial response progresses to the activation
of CD4+ T cells, which contribute additional cytokines
that are crucial to the development of fibrosis [63, 64].
Specifically the Th2 cytokines IL-4, IL-5, and IL-13 that
form the adaptive immune response are up regulated,
which are key fibrosis mediators [65–68]. Additionally,
production of IL-17 from Th17 cells and down regulation
of the Th1 response occurs in the fibrotic processes
[63, 64, 69]. This activation of an adaptive immune
response is independent of antigen sensitization [64],
but traditional antigen presenting cells like dendritic
cells may contribute to the inflammatory profile [70].
This signaling leads to the production of growth factors,
such as TGF-β, which are key regulators of fibroblast
activity, and their increased expression disrupts normal
homeostatic collagen metabolism, resulting in the exces-
sive collagen deposition in the extracellular matrix charac-
teristic of fibrotic lesions [66, 71]. Other mechanisms, for
example, direct stimulation of fibroblasts and epithelial
cells with bleomycin can lead to the release of
effector molecules [72], which may also contribute to
fibrosis in this model.
MWCNTs are non-biodegradable and persist in lung
tissues long after the initial exposure, resulting in pro-
longed tissue injury and unrestricted tissue repair. In
addition to their persistence, the high aspect ratio of
MWCNTs, their fibre-like structures, and chemical
groups on their surfaces are suggested to contribute to
the development of lung fibrosis [73], a potential human
health effect associated with occupational exposure to
MWCNTs [43]. Although several studies have reported
lung fibrosis following exposure to MWCNTs, the exact
underlying mechanisms are not completely elucidated.
Identifying specific mediators and a single mechanism
for MWCNT-induced pulmonary fibrosis is challenging.
Though data is more limited with respect to MWCNT
exposure models, the studies that are available highlight
the similarities between the pulmonary response to
MWCNTs and bleomycin [33, 74]. MWCNT-induced
inflammation, as indicated by neutrophil influx into the
lungs, is dependent on IL-1 signaling through the IL-1
receptor 1 (IL-1R1) [75], which involves the activation of
the NLRP3 inflammasome [76]. The characteristics of
the inflammatory response induced by MWCNTs paral-
lels the bleomycin model, which is reflected by the
induction of Th2-like phenotype, involving the produc-
tion of cytokines such as IL-13 [77, 78]. The inflam-
matory response ultimately leads to the alteration of
fibroblast activity resulting in enhanced activity of
TGF-β, which is also implicated in MWCNT-induced
fibrosis [79]; the TGF-β/SMAD pathway is involved in
fibroblast differentiation and epithelial mesenchymal
transition; another characteristic of fibrotic lesions [80].
Additional factors such as the generation of reactive
oxygen species have been shown to contribute to fibrotic
pathogenesis; animals deficient in anti-oxidant responses
elaborate exacerbated fibrosis in response to MWCNTs
[81]. While results from in vivo models described in the
present study suggest a role for pulmonary inflammation
in MWCNT-induced lung fibrosis, many in vitro studies
have suggested a plausible role for direct action of CNTs
(both MWCNTs and SWCNTs) on fibroblast function
and viability [77, 82–88] that may lead to fibrosis.
Moreover, these studies demonstrate increased fibro-
blast proliferation, collagen synthesis, and expression
of the fibrosis-associated gene Mmp9, all of which
serve as in vivo markers of lung fibrosis [77, 85–88].
However, these findings have not been confirmed
in vivo and additional research as to the relevance of
the direct stimulation of fibroblasts in isolation of all
of the other resident cells of the lung is necessary.
Thus, similar to the bleomycin model, multiple mech-
anisms likely contribute to MWCNT-induced fibrosis
but the focus on the inflammatory response triggered
by MWCNTs and the resulting pathology from these
pathways is warranted given the data generated from
models of MWCNT exposure.
It is important to note that other signaling pathways
not directly related to innate and adaptive immune
mechanisms may also contribute to MWCNT-induced
fibrosis (such as direct stimulation of fibroblasts by
CNTs), but the focus on the inflammatory response
triggered by MWCNTs and the resulting pathology from
these pathways is warranted given the crucial role that
inflammation is known to play in other models such as
bleomycin-induced or Th2-response triggered fibrosis.
Thus, based on the literature review of the general
mechanisms involved in lung fibrosis (described above),
and comprehensive analyses of gene expression profiles
perturbed following exposures to different doses of
MWCNTs at different post-exposure time-points, a hypo-
thetical AOP for pulmonary fibrosis was proposed accord-
ing to the guidance set by the Organisation for Economic
Cooperation and Development (OECD) [89–91]. The
AOP that we describe is a purposefully simplified linear
pathway constructed for the purposes of organising the
mechanistic data derived from the global gene expression
studies, and to facilitate selection of key pathways and
events to use for POD calculation. A full description of
the AOP, with the weight of evidence supporting the key
event relationships according to the modified Bradford-Hill
criteria described in the AOP Users’ Handbook, is beyond
the scope of this manuscript and is under development as
part of the OECD’s AOP program.
Thus, the putative AOP consists of a molecular initiating
event (MIE) and key events (KEs) vital to the development
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of lung fibrosis (Fig. 2). Although the networks and biology
involved in the development of lung fibrosis are very
complex, two criteria consistent with the OECD guidelines
were used in constructing the AOP: 1) the MIE and KEs
were based on their essentiality to the initiation and
progression of lung fibrosis (i.e., inhibition of occurrence of
these KEs would influence the final fibrosis outcome);
and 2) the MIE and KEs had to be measurable/quan-
tifiable. It is important to note that the putative AOP
described below is simplistic and reflects only one
potential mechanism, by which MWCNTs induce lung
fibrosis. We agree that there may be several converging
pathways that are involved in lung fibrosis. However, the
AOP program itself acknowledges that AOPs are purpose-
fully over-simplified linear pathways to toxicity (http://
aopkb.org/common/AOP_Handbook.pdf). The aim here
is to develop simple linear pathways that address con-
tained aspects of a pathway to toxicity. The AOPs should
contain only key events that are routinely measured (and
are essential), and subsequent to that the simplified linear
AOPs provide a basis to develop broader networks that
can be used in predictive toxicology. Accordingly, the
AOP for lung fibrosis induced by MWCNTs consisted of
the following steps:
MIE – Cellular sensing of the substance-induced
damage resulting in the release of danger signals.
KE1 - Induction of inflammatory cytokines and acute
phase response. This KE involves the recruitment and
infiltration of various immune cell types into the lung
tissue, which will clear the invading substance and
initiate the tissue repair process. This step is commonly
known as acute inflammation. Although a long list of
cytokines and chemokines are induced during the acute
inflammatory phase, since MWCNT-induced acute
inflammation is predominantly characterised by
neutrophil infiltration, we argue that IL-1R1-mediated
pathway is primarily involved in this process. Thus,
secretion of IL-1R1-regulated cytokines and chemokines
including IL1, IL6, CXCL-1, CCL2, CCL5, and SAA3, as
well as IL1β, can be used to measure KE1.
KE2 – a) Retention or repeated exposure and b)
persistent inflammation. The inability to clear
MWCNTs results in ‘frustrated phagocytosis’ leading to
prolonged interaction of MWCNTs with the lung
epithelium, continuous activation of stress signalling,
inflammatory response, and unremitting repair process.
The ensuing chronicity of inflammation engages the
adaptive immune system, which then results in the
third KE. Both KE 2a and 2b act in a positive feedback
loop and are essential for the activation of KE3.
Although ‘frustrated phagocytosis’ is suggested to occur
in response to specific-types of long MWCNTs, other
types of short or entangled MWCNTs including
NM-401 and NRCWE-026 also biopersist, which can
similarly result in chronicity of inflammation leading to
disruptive repair process.
KE3 - TH2/M2 response, secretion/activation of
interleukins and growth factors. This KE involves
activation of T helper (Th) 2 type cells and the release
of specific cytokines necessary for activation of M2 type
macrophages. M2 macrophages secrete anti-inflammatory
cytokines and tissue inhibitors of metalloproteinases that
impair remodelling or reabsorption of the deposited ECM.
Several TH2 type cytokines including IL-4, IL-5, IL-13 and
growth factors such as transforming growth factor beta,
that play an important role in the progression of lung
fibrosis are upregulated following exposure to MWCNTs
and can be used to quantify the activation of KE3.
KE4 – Fibroblast and myofibroblast proliferation. The
late stages of tissue injury involve chronic
inflammation, epithelial and endothelial injury, loss of
ACM integrity, and activation and proliferation of
fibroblasts/myofibroblasts.
KE5 – ECM deposition. The repeated cycles of the
preceding KEs result in excessive ECM deposition due
to imbalance between the deposition and metabolism
of ECM proteins, including collagen.
AO – fibrotic lesions. Excessive ECM deposition
results in the development of lung fibrotic lesions
(Adverse Outcome - AO).
In addition to the KEs described above, associative
events (AEs) occur in parallel and can enhance the prob-
ability that the exposure will lead to the AO. In this
AOP, the continual release of soluble mediators pro-
duced by the activated inflammatory cell types, and
subsequent interaction between the cell types, leads to
increased reactive oxygen species levels (AE1, oxidative
stress) and cellular apoptosis (AE2), which contribute to
repeated tissue injury (AE3). The other associative
events such as, resistance of fibroblasts to apoptosis,
collagen metabolism, or inhibition of collagen-degrading
enzymes may play a regulatory role in the progression of
lung fibrosis. Thus, these events are not included in the
hypothetical AOP presented and will be included in a
separate AOP.
The putative AOP as described above was subse-
quently used to categorize and prioritize the significantly
perturbed pathways and to calculate the median BMD(L)
values of genes within those pathways to derive pathway-
based PODs in an AOP-dependent transcriptomics ap-
proach (Fig. 1). The KE-associated BMDs were compared
with BMDs derived from analysis of conventional
toxicology endpoints (e.g., an apical endpoint asso-
ciated with fibrosis), and to AOP-independent tran-
scriptional approaches, to explore the best approach
to selection of a POD.
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In our previous studies, we have characterised tran-
scriptomic changes occurring in lungs of mice exposed
to carbon black (CB) or titanium dioxide nanoparticles
(TiO2NPs). In order to determine if the MIE and KEs in
the putative AOP described above for MWCNT-induced
lung fibrosis are also observed following exposure to
other control particles, such as CB or TiO2NPs, we
compared the pathways reported to be significantly per-
turbed following CB [22, 92] or TiO2NP [16] exposures
to those perturbed following exposure to MWCNTs.
The results showed that exposure to CB or TiO2NP
induces gene expression changes associated with lung
inflammation, Acute Phase Response Signaling and
Chemokine Signaling pathways [16, 22, 92] that are
relevant to MIE and KE1. However, it was noted that
the number of genes perturbed in each pathway was few
and the relative fold-changes were smaller compared to
the MWCNT-induced response. Moreover, most of the
significantly perturbed genes did not show dose–response
(data not shown), as a result they could not be modeled
using BMDExpress. These results suggested that although
CB and TiO2NP induce lung inflammation and induce
altered expression of genes and pathways associated with
MIE and KE1, the pro-fibrotic events described in KE2- 4
and AO are specific to MWCNTs. Thus, control par-
ticles were excluded from the rest of the analysis in
the present study.
Functional analysis of perturbed genes and dose–response
modeling
The BMD(L) values for all of the genes were calculated,
the genes were assigned to pathways, and median path-
way BMDs were thus calculated for each time-point and
for each MWCNT. The 3 days Poulsen et al. [19] and
7 days Guo et al. [44] time-points perturbed similar
pathways and since they represent early, acute post-
exposure time-points, they were considered together.
This also implies that the pathways leading to lung
fibrosis are activated as early as 3 days post-exposure;
however, the clinical manifestation as measured by
alveolar thickness may become apparent on 7 days after
the last exposure [93] (reviewed in [94]).
The lists of differentially expressed genes (DEGs)
derived from Poulsen et al. [19] and Guo et al. [44] were
analyzed for functional significance using IPA. The
significantly perturbed pathways (P < 0.05) were catego-
rized according to their association with the KEs and
AEs in the AOP for lung fibrosis. Pathways for which
the biology did not appear to be related to the KEs or
AEs in the AOP were not included in the analysis. A few
pathways overlapped with more than one KE: Chemokine
Signaling (KE1, KE3), Dendritic Cell Maturation (KE1,
KE3), Jak/Stat Signaling (KE1, KE3), Leukocyte Extrava-
sation (KE1, KE2), NF-kB Signaling (KE1, KE2), and
TGF-beta Signaling (KE3, KE4). The complete list of
perturbed pathways and the associated BMDs can be
found in Additional file 2: Table S2. Unique biological
pathways were perturbed at different post-exposure
time-points with some overlap. For example, Acute
Phase Response Signalling and Hepatic Fibrosis/Hep-
atic Stellate Cell Activation pathways were significantly
enriched at the 24 h, 3, and 28 days time-points for
NM-401. There is no separately annotated pathway for
lung fibrosis in IPA. The “Hepatic Fibrosis/Hepatic
Stellate Cell Activation” pathway includes pulmonary
fibrosis in the IPA pathway analysis tool. Fibrosis is a
wound healing process characterized by accumulation
of extracellular matrix and the components of ECM
accumulation are similar regardless of the cause or
tissue. Thus, for the rest of the discussion, this pathway
will be referred to as the ‘Fibrosis’ pathway. A large
number of biological pathways associated with the KEs
were perturbed 3 days post-exposure for all three types
of MWCNTs investigated. Thus, gene expression profil-
ing supports that the post-exposure time-points at
which the KE is observed has a strong influence on
whether it is measurably perturbed, which can be used
to support the temporal order of events.
In general, analysis of the distribution of pathway
BMDs revealed that most pathway BMD(L) values
(Fig. 3), including those associated with KEs, were lower
at the earlier time-points (24 h, 3 days) for NM-401 and
Mitsui-7. In contrast, NRCWE-026 had similar BMDs at
24 h and 3 days, but had very few pathways perturbed at
the 28 days time-point and only one KE-associated
BMD that could be derived for this time-point
(discussed below). Overall, some of the lowest BMD(L)
values were for pathways that were associated with more
than one KE and that were perturbed across MWCNTs
and time-points, including Chemokine Signaling, Den-
dritic Cell Maturation, and Jak/Stat Signaling. The
BMD(L) values were remarkably similar overall across
different time-points and MWCNT types. However, a
few exceptions were noted where BMD(L) values were
higher for the pathways perturbed at the later post-
exposure time-points (28 days), suggesting a time-
dependent transition in the toxicity pathways and that
the pathways implicated in the pathological manifest-
ation of the disease occur at the later time-points.
Thus, although different pathways were altered at
different post-exposure time-points, the BMD(L) values
within a KE were consistent across time-points and
particle types.
Interestingly, similar pathways were perturbed following
exposure to the three types of MWCNTs across the time-
points, despite differences in their physico-chemical
properties, suggesting that the underlying mechanisms
leading to fibrosis are the same for all three MWCNTs
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(Additional file 2: Table S2). For example, HMGB1 Signal-
ing, NF-kB Signaling, and Dendritic Cell Maturation were
perturbed at 3 days by NM-401 and NRCWE-026 and at
7 days by Mitsui-7. In addition, Acute Phase Response
was perturbed at 24 h, 3, and 28 days by NM-401 and
Agranulocyte Adhesion and Diapedesis was perturbed at
24 h, 7, 28, and 56 days by Mitsui-7. Additionally,
although the magnitude of changes in the expression
levels of the individual genes differed between the
MWCNT types [19, 44], which was reflected in the subtle
differences between the BMD(L) values for a specific path-
way for individual MWCNT types, the BMD(L) confi-
dence intervals across the MWCNT types overlapped
(Fig. 4). NRCWE-026 significantly altered a single pathway
28 days post-exposure (CDC42 Signaling). In addition, the
pathway BMD(L) values 3 days post-exposure were
relatively higher for this MWCNT than BMDL values at
3 days for NM-401 or at 7 days for Mitsui-7. BMDL values
ranged from 15.1 to 21.2 μg/mouse for NRCWE-026,
8.1–18.4 μg/mouse for NM-401, and 7.1–30.3 μg/
mouse for Mitsui-7. The lack of significant pathways
at 28-days post-exposure to NRCWE-026 corroborates
histopathological observations in the lungs: qualitative
assessment of the lung sections from mice exposed to
NRCWE-026 showed fewer incidences of fibrotic
lesions 28 days post-exposure than NM-401, as de-
scribed in Poulsen et al. [19]. Additional file 3: Figure
S1 depicts a heat map revealing the dose at which
each pathway was significantly perturbed. Given that
all three MWCNTs perturbed similar pathways across
doses and time-points, the results can be broadly
generalized to understand the potential lung re-
sponses induced by similar nanomaterials, and the
approach can be used as a sensitive alternative for
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Fig. 3 The distribution of pathway BMD-median values is influenced by post-exposure time. Distributions of pathway BMD-median values for
NM-401 (top), NRCWE-026 (center), and Mitsui-7 (bottom). Pathways were only considered in this analysis if they were significant (P < 0.05) with
five or more DEGs associated with them and if they had five or more molecules with goodness-of-fit P value > 0.1 and BMD/BMDL ratios < 10.
Overlain table indicates the median BMD(L) across all pathways for each time-point
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read across purposes and to identify properties that
are important for material toxicity.
Apical endpoint BMD(L)s
NIOSH conducted an extensive review of the literature
pertaining to the human health effects arising from
occupational exposures to both MWCNT and SWCNT
[43]. BMD(L)s for MWCNTs were derived using fibrosis-
related apical endpoint data (e.g., alveolar connective tis-
sue thickening, alveolar septal thickening, granulomatous
inflammation, and hydroxyproline amount) presented in
four individual studies [32–35] (Additional file 4:
Table S3). Only data from Mercer et al. [34] were
included in the present study for comparison of apical
24hr
BMD(L) ug/lung
3d/7d*
BMD(L) ug/lung
28d
BMD(L) ug/lung
MIE: Cellular sensing of substance
Toll-like Receptor Signaling Caveolar-mediated Endocytosis Signaling
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KE1: Induction of inflammatory cytokines and acute phase response
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JAK/Stat Signaling LPS/IL-1 Mediated Inhibition of RXR Function
IL-6 Signaling Chemokine Signaling/Dendritic Cell Maturation
Acute Phase Response 
Signaling
KE2: Retention or repeated exposure and persistent inflammation
IL-17 Signaling Leukocyte Extravasation Signaling
Leukocyte Extravasation 
Signaling
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Signaling NF-
Role of NFAT in Regulation of 
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Cyclins and Cell Cycle 
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Fig. 4 Pathways with the lowest BMD(L) values for each part of AOP per MWCNT and time-point. Figure shows the pathway with the lowest
BMDL for the MIE (Molecular Initiating Event) and each KE (Key Event) for NM-401 (solid black circles), NRCWE-026 (square with hatched lines), and
Mitsui-7 (star). The 95 % lower confidence interval (BMDL) for each BMD is represented by the error bars. Only significant canonical pathways
(P < 0.05, >5 genes) with BMD/BMDL ratios <10 and >5 genes modeled were included. The 3d/7d time-point with the asterisk (*) is a placeholder
for 7 days for Mitsui-7 as there was no 3 days time-point recorded. Blank spaces indicate no pathway was significant for that time-point. The KE5
only includes the pathway Fibrosis
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and transcriptomic PODs because: (a) the experimen-
tal design and the MWCNT studied was identical to
Guo et al. [44], which investigated the pulmonary
transcriptomic response; and (b) it is the only study
that examined apical endpoints in a mouse model,
which minimizes cross-species extrapolation. Morphomet-
ric analyses of histological sections for alveolar connective
tissue thickening, a biologically relevant event in pulmon-
ary fibrosis, were used in Mercer et al. [34] to calculate
apical endpoint BMD(L) values and to derive a POD. This
analysis revealed BMD and BMDLs of 27.1 and
14.1 μg/mouse, respectively for lung fibrosis induced
by Mitsui-7.
Approaches for deriving transcriptional PODs
Several different approaches were explored to determine
the best method to derive a transcriptional POD: 1) the
lowest BMD(L) value for any pathway, 2) the median
pathway BMD(L) value, 3) the lowest BMD(L) value
based on pathways related to the KE determined to be
the ‘point of no return’ (the initiation/occurrence of a
specific key event, beyond which the removal of the
toxic substance or inhibition of injury does not result in
the reversal of effects or recovery), and 4) the BMD(L)
value based on pathways related to lung fibrosis. These
approaches include AOP-independent (1 and 2) and
AOP-dependent approaches (3 and 4) for deriving a
transcriptional POD.
Approach 1, based on the most sensitive pathways
(Fig. 5a), yielded BMD(L)s between 7.1 (3.0) and 14.2
(8.2) μg/mouse for NM-401, 10.9 (4.9) and 20.2 (13.4)
μg/mouse for NRCWE-026, and 18.0 (2.8) and 23.0
(10.43) μg/mouse for Mitsui-7 across all post-exposure
time-points. For the most part, the BMD(L) values for
these pathways were below the NIOSH-calculated
BMD(L) of 27.1 (14.1) μg/mouse, which was based on
measuring alveolar thickness [34, 43]. The most sensitive
pathway approach has been recommended for deriving
PODs for cancer and non-cancer endpoints [28].
Although the pathways may be reflective of the tissue
a
c
b
d
Fig. 5 Comparison of BMD(L)s derived from four genomics approaches compared to the traditional NIOSH approach. Both AOP-independent
(approaches 1 and 2; panels (a) and (b), respectively) and AOP-dependent approaches (approaches 3 and 4; panels (c) and (d), respectively) are shown.
The grey lines represent the BMD (right bar) and BMDL (left bar) values for fibrosis apical endpoint [34, 43]. BMD values are represented by solid circles
for NM-401, hatched squares for NRCWE-026, and stars for Mitsui-7. The 95 % lower confidence interval (BMDL) for each BMD is represented by the
error bars. The 3 days/7 days time-point with the asterisk (*) is a placeholder for 7 days for Mitsui-7 as there was no 3 days time-point recorded
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injury caused by the initial interaction of MWCNTs with
the surrounding lung tissue, they were not consistently
observed across the types of MWCNTs, doses, or post-
exposure time-points. Moreover, their implication in the
final adverse outcome is less understood. Indeed, a POD
based on the most sensitive or lowest BMD(L) values
may not be based on a biological effect that is connected
to the adverse outcome. However, we note that there are
very few nanomaterials for which underlying mecha-
nisms of toxicity are characterized or a definite adverse
outcome has been identified. Thus, while this AOP-
independent approach may be too conservative, it would
serve to limit the exposure to particular nanomaterials
in the environment until specific hazard and mechanistic
information becomes available for them.
The median BMD(L) value approach, which is also
AOP-independent (based on BMDs for all pathways with
five or more DEGs associated with them and if they had
five or more molecules with goodness-of-fit P value > 0.1
and BMD/BMDL ratios < 10), represents a less conserva-
tive approach to POD selection (Fig. 5b). For the most
part, the BMD(L) values using this approach were above
the NIOSH-calculated BMD(L) of 27.1 (14.1) μg/mouse
with the exception of a few values (23.9 (15.1) μg/mouse
for Mitsui-7 at 24 h, 24.1 (15.3) μg/mouse for NM-401
at 3 days, and 25.6 (16.0) μg/mouse for NRCWE-026 at
28 days). However, the confidence intervals of the
median values (the median is the peak of biological
activity and represents the most robust central measure
of the response) were very close to the lower confidence
intervals of the NIOSH-calculated BMD and BMDL
values. Thus, without prior knowledge of the underlying
mechanism of toxicity or a definite adverse outcome, as
is the case with nanomaterials, this approach provides a
point at which the system is likely to be responding to
the exposure.
Transcriptional BMDs based on the AOP-dependent
approaches (approaches 3 and 4; Fig. 5c-d) resulted in
values consistent with the conventional fibrosis endpoint
(alveolar wall thickness, represented by grey bars in
Fig. 5). Of benefit in these approaches is the fact that
these pathway perturbations are biologically linked to
the AO, and thus it is biologically plausible that the
doses that affect these pathways might approximate the
dose at which adversity may arise. Modes of Action
(MOAs) have been routinely employed to inform risk
assessments for chemicals. However, MOA in the
conventional sense provides information concerning
molecular and cellular events engaged by the chemicals
in eliciting a response that is quantified but may or may
not always imply that the response will induce an
adverse outcome. AOPs have evolved from the concept
of MOAs, and also emphasize the importance of con-
necting various events that lead to toxicity. Both require
selection and ordering of the essential events that are
readily quantifiable along the pathway to toxicity, and
require assessment of empirical data (temporal and inci-
dence concordance) and biological plausibility support-
ing the relationship shared between events along the
pathway. In approaches 3 and 4, perturbed pathways
were characterized in terms of their association with
KEs, which provides a biological rationale for their
consideration in POD selection (if apical data are not
available). In approach 3, we selected a single KE (KE3:
Th2 Signaling activation), the activation of which we
argue marks the ‘point of no return’ in the process of
developing lung fibrosis. The various pathways involved
in KE3 including Dendritic Cell Maturation, Cdc42
Signalling, T Helper Cell Differentiation, Fcy Receptor-
Mediated Phagocytosis in Macrophages and Monocytes,
Chemokine Signalling, JAK/Stat Signalling, and PKC
Theta Signalling in T Lymphocytes, showed BMDs that
spanned the POD range published by NIOSH for the
apical endpoint of concern (alveolar connective tissue
thickening) (Fig. 5c). In approach 4, the POD selection
was based on a pathway tied directly to the AO, which is
the lung fibrosis pathway described under KE5. How-
ever, in our case, the BMDs based on the pathways asso-
ciated with fibrosis (the ultimate result of exposure to
MWCNTs) were less consistent for the three MWCNTs
and across the different exposure time-points (Fig. 5d)
relative to the other three approaches. The inconsisten-
cies may be due to the fact that representative pathways
for fibrosis were not significant across the MWCNT
types, doses and post-exposure time-points.
Taken together, the four approaches for transcriptional-
or pathway-based POD derivation produced comparable
results across time-points and across the three types of
MWCNTs. The confidence intervals between datasets
often overlapped; however, the AOP-centered approach
based on the ‘point of no return’ KE (approach 3) and
the median BMD approach (approach 2) more closely
reflected the histopathological observations demon-
strating alveolar thickness that are critical for the
development of fibrosis.
It is important to note that although the individual
MWCNTs varied in their physico-chemical properties,
all of them bio-persist long after the exposure and
exhibit potential to induce lung fibrosis. In addition, at
the molecular level, they induced similar pathway
perturbations and BMD(L) values suggesting that the
mechanisms underlying the fibrotic responses are the
same for the three MWCNTs. The fact that all three
MWCNT types induce similar response at the pathway
level is interesting and suggests that all MWCNTs are
inherently capable of inducing lung fibrosis, which may
be associated with their fiber-like shape and tissue
biopersistence. However, some MWCNTs may be more
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potent than others in inducing lung fibrosis, which could
be attributed to their additional physico-chemical proper-
ties such as chemical impurities, surface functionalization,
etc. Previously, we have shown that subtle differences in
the degree of pathway perturbation somewhat reflects the
extent of fibrosis development [19]. In another study, we
have shown that changes in the gene expression levels and
pathway perturbations can effectively discriminate be-
tween the nanoTiO2 particles that are weak or strong
inducers of lung inflammation [16]. Collectively, these
results suggest that transcriptomic responses are a sensi-
tive approach to identifying potentially harmful nanoma-
terials and that the transcriptomic BMD(L)s can be used
to establish acceptable levels of exposure for new nanoma-
terials. As the public repository of genomics dataset is
populated and the underlying mechanisms of toxicity are
revealed, these types of data can be used in read across
and category approaches for risk assessment.
Conclusions
In conclusion, the results show that transcriptomics-
derived PODs accurately reflect the levels of exposure to
MWCNTs at which lung fibrosis potentially develops in
animals. The significant overlap in pathway responses
induced by the different types of MWCNTs and com-
parable pathway-based POD values suggests that the
approach can be generalised to other forms of MWCNTs.
This study demonstrates that in the absence of any apical
endpoint toxicological data conventionally preferred in
HHRA, transcriptomics data can be used to inform the
potential hazards of these novel materials and to support
interim regulatory decisions. We speculate that this
toxicogenomics/AOP approach will be of value for predic-
tion of fibrogenic potency and hazard ranking of different
MWCNTs. The case study is limited to the analysis of in
vivo genomics data and its applicability to HHRA, but
we emphasize that this approach does not represent a full
risk assessment. While analysis of a well-characterized
nanomaterial known to induce adverse effects provides an
initial framework for future studies, regulatory validation
of these methods will require a large repository of publicly
available high quality gene expression data that span sev-
eral well-characterised reference nanomaterials of diverse
properties, multiple doses, a range of post-exposure time-
points, and multiple species. Guidance and appropriate
criteria for assessing experimental design and quality of
data produced, rigorous statistical and computational
algorithms to handle the large amount of data, and
harmonised guidelines for integrating omics data into
HHRA are needed. Finally, given the complexity of data,
education and training programs for researchers and risk
assessors in the generation, analysis, and application of
omics data to different components of the risk assessment
paradigm should be developed.
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